The Life Sciences team advised InterVenn Biosciences in the completion of its $201 million Series C financing. The funding round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
The proceeds from the financing will be used to accelerate development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
The Goodwin team was led by Maggie Wong and Kingsley Taft and included Alexander Varond, Lauren Tjoe, Daniel Karelitz, William Stern and Jacob Osborn.
For additional details on the financing round, please read the press release and coverage in FierceBiotech, San Francisco Times, BioSpace and Precision Oncology News.